Disclosed is an isolated antibody or binding fragment thereof that specifically binds to PDGFR-alpha and inhibits the growth of cells that express PDGFR-alpha. The disclosed antibody comprises: a heavy chain complementarity determining region (CDR) 1 comprising the amino acid sequence GFTFSDYYMH； a heavy chain CDR2 comprising the amino acid sequence ISRSGSLIYYVDSVKG； a heavy chain CDR3 comprising the amino acid sequence GGPYSGSPFDY； a light chain CDR1 comprising the amino acid sequence RPSQRISRYLN； a light chain CDR2 comprising the amino acid sequence AASSLPS； and a light chain CDR3 comprising the amino acid sequence QQSYSTPPWT. The disclosed antibody is used in the treatment of neoplastic diseases including cancer.
